Now showing items 1-4 of 4

    • Clinical and Molecular Spectrum of Liposarcoma. 

      Lee, ATJ; Thway, K; Huang, PH; Jones, RL (2018-01)
      Liposarcomas are rare malignant tumors of adipocytic differentiation. The classification of liposarcomas into four principal subtypes reflects the distinct clinical behavior, treatment sensitivity, and underlying biology ...
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. 

      Sundar, R; McVeigh, T; Dolling, D; Petruckevitch, A; Diamantis, N; Ang, JE; Chenard-Poiriér, M; Collins, D; Lim, J; Ameratunga, M; Khan, K; Kaye, SB; Banerji, U; Lopez, J; George, AJ; de Bono, JS; van der Graaf, WT (2018-09)
      BACKGROUND:Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM:To ...
    • Implementing the EffTox dose-finding design in the Matchpoint trial. 

      Brock, K; Billingham, L; Copland, M; Siddique, S; Sirovica, M; Yap, C (2017-07-20)
      The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation ...
    • International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 

      Terpos, E; Morgan, G; Dimopoulos, MA; Drake, MT; Lentzsch, S; Raje, N; Sezer, O; García-Sanz, R; Shimizu, K; Turesson, I; Reiman, T; Jurczyszyn, A; Merlini, G; Spencer, A; Leleu, X; Cavo, M; Munshi, N; Rajkumar, SV; Durie, BGM; Roodman, GD (2013-06)
      The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.An interdisciplinary panel of clinical experts on MM and myeloma ...